Lonza expanded cytotoxic manufacturing capabilities in Visp, Switzerland to serve the growing oncology API market. Cytotoxic APIs are commonly used in oncology therapeutics, which represent one of the fastest growing segments of the pharma and biotech industry.
Lonza invested in a formulation plant for Meta™ metaldehyde for slug and snail control. This enabled Lonza to supply its own formulations, allowing Lonza to better serve the market not only with metaldehyde as an active substance, but also with ready-made slug pellets.
Lonza celebrated 40 years as leading producer of vitamin B3. Since 1971, Lonza has supplied more than half the world’s demand for vitamin B3 in the human and animal health nutrition industries.
In its largest-ever acquisition to date, Lonza acquires Arch Chemicals, Inc., a global biocides company providing innovative solutions to destroy or to selectively inhibit the growth of harmful microorganisms, to create the world’s leading Microbial Control business. The combined businesses were well positioned to develop innovative microbial control formulations based on a broad portfolio of registered and approved active ingredients.
Lonza Group Ltd (SIX stock code: LONN VX; SGX-ST stock code: O6Z) made its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited on 21 October 2011 and consequently was the first SIX Swiss-listed company to dual list in Singapore.